Kura Oncology Inc (KURA) concluded trading on Thursday at a closing price of $8.82, with 5.7 million shares of worth about $50.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.92% during that period and on February 06, 2025 the price saw a loss of about -2.54%. Currently the company’s common shares owned by public are about 77.75M shares, out of which, 65.24M shares are available for trading.
Stock saw a price change of 9.84% in past 5 days and over the past one month there was a price change of 3.64%. Year-to-date (YTD), KURA shares are showing a performance of 1.26% which decreased to -57.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.98 but also hit the highest price of $24.17 during that period. The average intraday trading volume for Kura Oncology Inc shares is 2.07 million. The stock is currently trading 12.33% above its 20-day simple moving average (SMA20), while that difference is down -2.08% for SMA50 and it goes to -48.25% lower than SMA200.
Kura Oncology Inc (NASDAQ: KURA) currently have 77.75M outstanding shares and institutions hold larger chunk of about 97.63% of that.
The stock has a current market capitalization of $685.87M and its 3Y-monthly beta is at 0.83. It has posted earnings per share of -$2.36 in the same period. It has Quick Ratio of 11.47 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KURA, volatility over the week remained 10.61% while standing at 6.53% over the month.
Stock’s fiscal year EPS is expected to drop by -17.81% while it is estimated to increase by 25.34% in next year. EPS is likely to grow at an annualized rate of 2.42% for next 5-years, compared to annual growth of -3.94% made by the stock over the past 5-years.
Coverage by UBS stated Kura Oncology Inc (KURA) stock as a Buy in their note to investors on October 24, 2024, suggesting a price target of $27 for the stock. On October 14, 2024, Stifel Downgrade their recommendations, while on December 22, 2023, Mizuho Initiated their ratings for the stock with a price target of $26. Stock get a Buy rating from BofA Securities on August 11, 2023.
